Esophageal / Gastrointestinal Cancer Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Description: The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Description: The main purpose of this study is to compare how long subjects with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab compared with patients receiving chemotherapy standard of care, oxaliplatin plus fluoropyrimidine

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, who have gastric cancer or gastroesophageal junction cancer that cannot be operated on and that is advanced or has spread out

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Description: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects 18 y/o and older, who have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma of the gastrointestinal (GI) tract

Status

Please contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

 

Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments

Description: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, with a histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction and who have previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy

Status

Active and open to enrollment

Contacts

Brenda Eng, 415-600-1775